Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Daiichi Sankyo
US Army
Medtronic
Accenture
Colorcon
Cipla
AstraZeneca

Generated: April 23, 2018

DrugPatentWatch Database Preview

SITAVIG Drug Profile

« Back to Dashboard

Which patents cover Sitavig, and when can generic versions of Sitavig launch?

Sitavig is a drug marketed by Epi Hlth and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-six patent family members in twenty-five countries.

The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
Summary for SITAVIG
Drug patent expirations by year for SITAVIG
Medical Subject Heading (MeSH) Categories for SITAVIG
Synonyms for SITAVIG
141294-79-3
1pwy
2-?AMINO-?1,?9-?DIHYDRO-?9-?[(2-?HYDROXYETHOXY)METHYL]-?6H-?PURIN-?6-?ONE
2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one
2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one
2-amino-9-((2-hydroxyethoxy)methyl)-1,9-dihydro-6H-purin-6-one
2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6H-purin-6-one
2-amino-9-((2-hydroxyethoxy)methyl)-3H-purin-6(9H)-one
2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one
2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (ACV)
2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one
2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one
2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one
2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one #
2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one
2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one
2-amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol
2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one
2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-azanyl-9-(2-hydroxyethyloxymethyl)-3H-purin-6-one
277A893
32284-EP2281815A1
32284-EP2301933A1
32284-EP2311827A1
59277-89-3
6383-EP2270005A1
6383-EP2305243A1
6383-EP2305640A2
6383-EP2305808A1
6383-EP2314582A1
6383-EP2314585A1
69657-51-8 (Na salt)
6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)-methyl)-
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-
6H-Purin-6-one,2-amino-1,9-dihydro-9-((2-hydroxyethoxy)mehtyl)
9-((2-Hydroxyethoxy)methyl)guanine
9-(2-hydroxyethoxy methyl) guanine
9-(2-Hydroxyethoxy)methylguanine
9-(2-Hydroxyethoxymethyl)guanine
9-[(2-Hydroxyethoxy)- methyl]guanine
9-[(2-Hydroxyethoxy)-methyl]guanine
9-[(2-Hydroxyethoxy)-methyl]guanine;Acyclovir
9-[(2-Hydroxyethoxy)methyl]guanine
9-HYROXYETHOXYMETHYLGUANINE
9(2-hydroxyethoxymethyl)guanine
A 4669
A832236
AB0012294
AB0068584
AC-8068
AC1L1CR6
AC2
Acic
Acicloftal
Aciclovier
Aciclovir
Aciclovir (JAN/INN)
Aciclovir (JP17/INN)
Aciclovir [INN]
Aciclovir 1.0 mg/ml in Dimethyl Sulfoxide
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard
Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard
Aciclovir granules (JP17)
Aciclovir ophthalmic oinment (JP17)
Aciclovir sodium
Aciclovir tablets (JP17)
Aciclovir, Acycloguanosine, Zovirax, Acyclovir
Aciclovir, European Pharmacopoeia (EP) Reference Standard
Aciclovirum
Aciclovirum [INN-Latin]
Aciclovirum [Latin]
Acivir (TN)
Acivirax (TN)
Activir
ACV & Pluronic F-68
Acyclo-V
AcycloFoam
Acycloguanosine
Acycloguanosine, >=99% (HPLC), powder
acyclovir
Acyclovir (Aciclovir)
Acyclovir (USP)
Acyclovir [USAN:USP]
Acyclovir [USAN]
Acyclovir & Pluronic F-68
Acyclovir Lauriad
ACYCLOVIR SODIUM
Acyclovir-side chain-2-3H
ACYCLOVIR-SIDECHAIN-2-3H
Acyclovir, pharmaceutical secondary standard; traceable to USP, PhEur and BP
Acyclovir, United States Pharmacopeia (USP) Reference Standard
AJ-26665
AK-24687
AKOS000656213
AKOS015995680
AKOS022135433
Alti-Acyclovir
AM20100442
AN-8358
ANW-43941
ARONIS27002
Avirax
B-LF& ACV
BAS 00485787
BB_NC-0569
BBL009642
BC201598
BDBM50021776
BDBM50103518
BIDD:GT0646
Bovine lactoferrin & 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one
BPBio1_000014
BR-24687
BSPBio_000012
BSPBio_003348
BW 248U
BW-248-U
BW-248U
BW-248U74
C06810
C8H11N5O3
Cargosil
CAS-59277-89-3
CCG-39909
CCRIS 1953
CHEBI:2453
CHEMBL184
CJ-05206
CPD000058225
CS-1353
CTK3J2211
Cyclovir
Cyclovir (TN)
D00222
D0B5MP
D0Y9QQ
DB00787
DivK1c_000185
DRG-0008
DSSTox_CID_2556
DSSTox_GSID_22556
DSSTox_RID_76626
DTXSID1022556
EBD48195
EINECS 261-685-1
EU-0100037
F2173-0946
FT-0082883
FT-0621607
FT-0657847
Genvir
GTPL4829
Hascovir
HE048648
HE249233
HE357443
HE358276
Herpex (TN)
HMS1568A14
HMS1922E08
HMS2090G09
HMS2095A14
HMS2234K21
HMS3259N10
HMS3260G15
HMS3269M15
HMS3372K02
HMS3655C14
HMS500J07
HSDB 6511
HY-17422
I01-1122
IDI1_000185
InChI=1/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15
iontophoretic acyclovir
J10243
KBio1_000185
KBio2_002219
KBio2_004787
KBio2_007355
KBio3_002850
KBioGR_000889
KBioSS_002219
KS-00000FAT
KS-000048I2
KS-1027
KSC492E1D
Lopac-A-4669
Lopac0_000037
LP00037
LS-127209
M-1904
Maynar
MCULE-2703274259
MFCD00057880
MKUXAQIIEYXACX-UHFFFAOYSA-N
MLS000069633
MolPort-000-768-994
MolPort-001-889-834
MolPort-003-940-063
NC00717
NCGC00015061-01
NCGC00015061-02
NCGC00015061-03
NCGC00015061-04
NCGC00015061-05
NCGC00015061-06
NCGC00015061-07
NCGC00015061-08
NCGC00015061-09
NCGC00015061-10
NCGC00015061-12
NCGC00015061-13
NCGC00022426-03
NCGC00093555-01
NCGC00093555-02
NCGC00093555-03
NCGC00093555-04
NCGC00167756-01
NCGC00167756-02
NCGC00260722-01
NINDS_000185
NSC 645011
NSC-645011
NSC-758477
NSC645011
NSC758477
Opera_ID_1674
Pharmakon1600-01503603
Poviral
Prestwick_6
Prestwick0_000086
Prestwick1_000086
Prestwick2_000086
Prestwick3_000086
PubChem9572
Q-200591
RP27589
s1807
SAM002589967
SBB063281
SC-05587
SCHEMBL3175
SCHEMBL9828560
Sitavig (TN)
Sitavir
SMP1_000007
SMR000058225
SPBio_001466
SPBio_001951
Spectrum_001739
SPECTRUM1503603
Spectrum2_001563
Spectrum3_001874
Spectrum4_000225
Spectrum5_001093
SR-01000075540
SR-01000075540-1
ST024744
STK796771
STL257059
STL301862
TL8003779
Tox21_110075
Tox21_110075_1
Tox21_500037
UNII-X4HES1O11F
Vipral
Virolex
Viropump
Virorax
W-248-U
Wellcome-248U
X4HES1O11F
ZINC1530555
Zovir
Zovir (TN)
Zovirax
Zovirax (TN)
Zovirax Oral Acyclovir (ACV) Suspension
Zovirax topical
Zyclir

US Patents and Regulatory Information for SITAVIG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for SITAVIG

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,211,466 Mucosal bioadhesive slow release carrier for delivering active principles ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for SITAVIG

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038 France ➤ Try a Free Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Teva
Healthtrust
Citi
Chinese Patent Office
Merck
Cantor Fitzgerald
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.